Corcept Therapeutics Inc (CORT) reports increased revenue and expanding market opportunities, despite facing operational hurdles and ongoing litigation.

Biopharma company Corcept Therapeutics (NASDAQ:CORT) in Q1 CY2025, but sales rose 7.1% year on year to $157.2 million. On the ...

Corcept attributed the revenue shortfall to supply chain issues at its specialty pharmacy vendor early in the quarter, which impacted its ability to fulfill a surge in demand. The company noted that ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

The Company expects to submit a New Drug Application to the Food and Drug Administration in the third quarter of 2025.

A panelist discusses how education and cost are key challenges in ensuring comprehensive molecular testing is performed in a ...

A panelist discusses how multiple molecular biomarkers beyond BRCA and homologous recombination deficiency (HRD) testing are ...

The FDA has granted fast track designation to INX-315 for the treatment of CCNE1-amplified, platinum-resistant/refractory ovarian cancer.

We recently published a list of Billionaire Jim Simons’ RenTech’s 10 Small-Cap Stock Picks with Huge Upside Potential.

One of the losers of today's trading session was Corcept Therapeutics ... which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol ...

Patients with stage IV ovarian cancer can derive long-term benefits from neoadjuvant pembrolizumab and chemotherapy if they achieve a major pathologic response, according to research published in ...

Akeso Inc. scored U.S. FDA approval of the PD-1 monoclonal antibody penpulimab in combination with cisplatin or carboplatin and gemcitabine for the first-line treatment of adult recurrent or ...